Mersana Therapeutics
Presence
Mersana Therapeutics is one of the...
Mersana Therapeutics is a company listed under the stock ticker MRSN (US).
Executives
View the org chart displaying its 19 main executives
Most searched biographies at Mersana Therapeutics
- Martin Huber, Director, President and Chief Executive Officer
- Anna Protopapas, Director
- Kristen Hege, Director
Popular executive movements at Mersana Therapeutics
- Martin Huber, who was Director, is promoted to Director, President and Chief Executive Officer (posted on September 7 2023).
- Brian DeSchuytner, who was Senior Vice President and Chief Financial Officer, is promoted to Senior Vice President, Chief Operating Officer and Chief Financial Officer (posted on September 7 2023).
- Mohan Bala, who was Senior Vice President, Strategic Product Planning & Program Leadership, is promoted to Senior Vice President and Chief Development Officer (posted on September 7 2023).
Create your alert
to follow the executive moves at Mersana Therapeutics.
Biotechnology
Mersana Therapeutics has 2,282 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Mersana Therapeutics
- Press Releases - Mersana Therapeutics
- Mersana Therapeutics to Present Preclinical Data from Immunosynthen STING-Agonist ADC Platform at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting - Mersana Therapeutics
- Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study - Mersana Therapeutics
- Mersana Therapeutics to Present Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study at the 2020 ESMO Virtual Congress - Mersana Therapeutics
- Mersana Therapeutics to Present at Upcoming Investor Conferences - Mersana Therapeutics
- Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Mersana Therapeutics
- Mersana Therapeutics Appoints Chuck Miller as Senior Vice President of Regulatory Affairs - Mersana Therapeutics
- Mersana Therapeutics Receives FDA Fast Track Designation for XMT-1536 for the Treatment of Patients with Platinum-resistant Ovarian Cancer - Mersana Therapeutics
- Mersana Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update - Mersana Therapeutics
- Mersana Therapeutics to Present at Upcoming Investor Conferences - Mersana Therapeutics
- View more press releases Close
Social media about Mersana Therapeutics
- Mersana Therapeutics on Wikipedia, Google News & Yahoo Finance
- Mersana Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Anna Protopapas 
Call Mersana Therapeutics at +1 617...
